GT Biopharma Inc (GTBP) Stock Analysis
Verdict: AVOID
Massive share dilution and rapid cash burn offset Phase 1 TriKE clinical progress, making survival dependent on toxic preferred equity.
Investment score: 19/100
Analysis as of
Is GT Biopharma Inc stock worth reviewing? The TradeMates thesis
The TradeMates model assigns an investment score of 19/100 and recommends AVOID for GTBP. Despite Phase 1 progress in its NK-cell engager pipeline, aggressive share dilution and toxic preferred financing structures erode common shareholder value.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 35/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
GT Biopharma Inc opportunities and risks
What speaks for GTBP
- FDA clearance of IND for GTB-5550 in Multiple Myeloma on September 15, 2026
What speaks against GTBP
- Toxic Series M Preferred Equity and Warrant Overhang
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| GTBP | n/a | 0.0x | n/a | 0.0% | 0.0% | -211.3% |
| CNSY | n/a | 3.1x | n/a | 89.6% | -620.7% | -179.4% |
| CLRB | n/a | 0.0x | 0.9x | 0.0% | 0.0% | -161.0% |
| AEON | n/a | 0.0x | n/a | 0.0% | 0.0% | -113.9% |
| PASG | n/a | 0.0x | 0.4x | 0.0% | 0.0% | -290.0% |
| BIVI | n/a | 0.0x | n/a | 0.0% | 0.0% | -173.9% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -173.9% |
Frequently asked questions about GT Biopharma Inc (GTBP)
Is GTBP stock a good investment?
The TradeMates model rates GT Biopharma Inc as AVOID with an investment score of 19/100. The TradeMates model assigns an investment score of 19/100 and recommends AVOID for GTBP. Despite Phase 1 progress in its NK-cell engager pipeline, aggressive share dilution and toxic preferred financing structures erode common shareholder value. This is algorithmic model output, not personal investment advice.
Is GTBP stock a buy?
The TradeMates model verdict for GTBP is AVOID with an investment score of 19/100. Treat this as a model signal to review, not a personal buy recommendation.